Immunovant says IMVT-1402 cutaneous lupus study misses primary endpoint, halts CLE development

By Public Technologies
  • Immunovant reported topline results from a proof-of-concept trial of IMVT-1402 in cutaneous lupus erythematosus.
  • The study missed its primary goal, prompting Immunovant to halt development of IMVT-1402 in this indication.
  • Results showed favorable directional signals on several measures, with stronger antibody reductions linked to better clinical responses.
  • Safety and tolerability remained consistent with prior studies, with no new concerns highlighted.
  • Other IMVT-1402 development programs remain on schedule across multiple autoimmune diseases.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunovant Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609230700PRIMZONEFULLFEED9832130) on September 23, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.